Sangamo Therapeutics

Youtube Subscribe

Open: 0.4 Close: 0.36 Change: -0.04

What an AI can tell you about Sangamo Therapeutics before investing.

This document will help you to evaluate Sangamo Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sangamo Therapeutics are: Sangamo, Therapeutics, NASDAQSGMO, negative, Inc, Receives, Average, …

Concept Map

Semantic Network

Stock Summary

Sangamo Therapeutics, Inc. focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy.

Today's Summary

Sangamo Therapeutics (NASDAQ:SGMO) Receives Average Recommendation of “Hold” from Brokerages Posted by Defense World Staff on Dec 20th, 2023.

Today's News

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of “Hold” from Brokerages Posted by Defense World Staff on Dec 20th, 2023. Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report ) last issued its quarterly earnings results on Wednesday, November 1st. Sangamo has a negative net margin of 123.88% and a negative return on equity of 61.40% Analysts predict that Sangamo will post -0.82 EPS for the current year. This weeks episode features a conversation with Sangamo Therapeutics CEO Sandy Macrae, Ph.D., who rationalizes the companys aggressive pipeline development and its decision to invest in multinational AAV and cell therapy manufacturing facilities in France and California. AP holds stocks in small amounts from BioNTech SE.

Stock Profile

"Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California."

Keywords

How much time have you spent trying to decide whether investing in Sangamo Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sangamo Therapeutics are: Sangamo, Therapeutics, NASDAQSGMO, negative, Inc, Receives, Average, and the most common words in the summary are: therapeutic, pharmaceutical, inc, company, therapy, sangamo, biotech, . One of the sentences in the summary was: Sangamo Therapeutics (NASDAQ:SGMO) Receives Average Recommendation of “Hold” from Brokerages Posted by Defense World Staff on Dec 20th, 2023.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #pharmaceutical #inc #company #therapy #sangamo #biotech.

Read more →

Youtube Subscribe

---